<div id="readability-page-1"><p>Luminus Management LLC trimmed its stake in shares of  Mersana Therapeutics, Inc. (NASDAQ:MRSN - Free Report) by 95.2% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor  owned 50,000 shares of the company's stock after selling 989,314 shares during the quarter. Mersana Therapeutics makes up  about  0.3% of Luminus Management LLC's portfolio, making the stock its 15th largest holding. Luminus Management LLC owned about 1.00% of Mersana Therapeutics worth $388,000 as of its most recent filing with the Securities and Exchange Commission (SEC).</p><div><p><span></span><span>Get <strong>Mersana Therapeutics</strong> alerts:</span></p></div><p>A number of other hedge funds also recently modified their holdings of the business. Invesco Ltd. grew its stake in shares of  Mersana Therapeutics by 109.3% in the first quarter. Invesco Ltd. now owns 114,863 shares of the company's stock worth $40,000 after purchasing an additional 59,991 shares during the last quarter.  Algert Global LLC lifted its holdings in  Mersana Therapeutics by 124.7% during the 1st quarter. Algert Global LLC now owns 135,013 shares of the company's stock worth $46,000 after buying an additional 74,930 shares during the period.  Cerity Partners LLC grew its position in shares of  Mersana Therapeutics by 31.4% in the 2nd quarter. Cerity Partners LLC now owns 320,805 shares of the company's stock valued at $95,000 after buying an additional 76,570 shares during the last quarter.  JPMorgan Chase &amp; Co. increased its stake in shares of  Mersana Therapeutics by 156.6% in the second quarter. JPMorgan Chase &amp; Co. now owns 130,094 shares of the company's stock valued at $39,000 after buying an additional 79,390 shares during the period.  Finally, Jacobs Levy Equity Management Inc. increased its stake in shares of  Mersana Therapeutics by 19.9% in the first quarter. Jacobs Levy Equity Management Inc. now owns 1,333,124 shares of the company's stock valued at $459,000 after buying an additional 221,126 shares during the period. Institutional investors and hedge funds own  93.92% of the company's stock. </p><h2>Mersana Therapeutics Price Performance</h2><p>NASDAQ MRSN opened at $28.59 on Tuesday. The company has a fifty day moving average price of $17.84 and a 200-day moving average price of $11.35. Mersana Therapeutics, Inc. has a 1 year low of $5.21 and a 1 year high of $56.00. The firm has a market cap of $142.95 million, a price-to-earnings ratio of -2.06 and a beta of 0.43. </p><p>Mersana Therapeutics (NASDAQ:MRSN - Get Free Report) last posted its quarterly earnings data on Friday, November 14th. The company reported ($1.51) EPS for the quarter, missing the consensus estimate of ($1.44) by ($0.07). The business had revenue of $11.01 million for the quarter, compared to analysts' expectations of $14.20 million.  On average, research analysts anticipate that  Mersana Therapeutics, Inc. will post -0.62 EPS for the current fiscal year. </p><h2>Analysts Set New Price Targets</h2><p>Several analysts recently commented on the company. Leerink Partnrs cut Mersana Therapeutics from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Thursday, November 13th. Lifesci Capital downgraded Mersana Therapeutics from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research note on Thursday, November 13th. BTIG Research cut Mersana Therapeutics from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research note on Thursday, November 13th. Weiss Ratings  restated a &#34;sell (e+)&#34; rating on shares of Mersana Therapeutics in a report on Monday, December 8th. Finally, William Blair cut Mersana Therapeutics from a &#34;strong-buy&#34; rating to a &#34;market perform&#34; rating in a report on Thursday, November 13th. Seven analysts have rated the stock with a Hold rating and one  has given a Sell rating to the stock. Based on data from MarketBeat, the stock  has an average rating of &#34;Reduce&#34; and an average target price of $38.19.</p><p><b>Read Our Latest Stock Report on MRSN</b></p><h2>Mersana Therapeutics Profile</h2> (Free Report)<p>Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Mersana Therapeutics</li><li>Consumer Discretionary Stocks Explained</li><li>Pfizer Adds to Its Big Bet on Weight Loss Drugs</li><li>How to Plot Fibonacci Price Inflection Levels </li><li>ServiceNow’s $7 Billion Gamble: Panic or Opportunity?</li><li>What is the S&amp;P/TSX Index?</li><li>Dell and HP Are Raising Prices—And Investors Should Take Note</li></ul><p><strong>Want to see what other hedge funds are holding MRSN?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mersana Therapeutics, Inc. (NASDAQ:MRSN - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TVJTTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TVJTTg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Mersana Therapeutics Right Now?</h2><p>Before you consider Mersana Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mersana Therapeutics wasn't on the list.</p><p>While Mersana Therapeutics currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

MRSN

<p>Luminus Management LLC reduced its stake in Mersana Therapeutics by 95.2%, selling 989,314 shares in Q3. Mersana's stock performance shows a 1-year low of $5.21 and high of $56.00, with a market cap of $142.95 million. Analysts have downgraded the stock to 'Hold' or 'Sell', with an average target price of $38.19. Mersana develops ADCs for cancer treatment.</p>

Luminus Management LLC Sells 989,314 Shares of Mersana Therapeutics, Inc. $MRSN